India, Aug. 25 -- AbCellera Biologics Inc. (ABCL), a clinical-stage biotechnology company developing antibody-based medicines, recently reported second-quarter 2026 financial results and provided updates across its clinical pipeline and strategic collaborations.
For the second quarter of 2026, AbCellera reported revenue of $4.1 million, compared with $17.1 million in the prior year quarter.
Research and development expenses increased to $46.0 million from $39.2 million, while sales, general and administrative expenses declined to $13.9 million from $22.0 million.
Net loss widened to $55.4 million, or $0.18 per share, compared with a net loss of $34.7 million, or $0.12 per share, in the second quarter 2025.
AbCellera ended the quarter wi...